A study of navitoclax and ruxolitinib for myelofibrosis (TRANSFORM 2)

This study is comparing navitoclax and ruxolitinib with usual treatment for myelofibrosis. It is for people whose myelofibrosis has come back.

The bone marrow is where we make our blood cells. Myelofibrosis is a rare blood disorder. It causes scarring of the bone marrow so it can’t make blood cells properly.

Myelofibrosis can develop without having had any other medical condition. This is called primary myelofibrosis. It can also develop in people who have polycythaemia vera or thrombocythaemia. This is called secondary myelofibrosis.

This study is for people with either primary or secondary myelofibrosis.